RecruitingEarly Phase 1NCT07429461
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhejiang University
- Intervention
- SYNCAR-100 Injection(drug)
- Enrollment
- 16 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2041
Study locations (1)
- The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Collaborators
Bisheng (Beijing) Biotechnology Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07429461 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05263583Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaCothera Bioscience, Inc